Previous close | 3.5000 |
Open | 3.5000 |
Bid | 2.2000 |
Ask | 3.8000 |
Strike | 5.00 |
Expiry date | 2024-08-16 |
Day's range | 3.5000 - 3.5000 |
Contract range | N/A |
Volume | |
Open interest | 300 |
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Peter Garcia, Chief Financial Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), purchased 12,000 shares of the company on June 13, 2024, as reported in a recent SEC Filing.